16:17 EST Regenxbio (RGNX) files $300M mixed securities shelf
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- RegenXBio’s Strategic Manufacturing and Commercial Readiness Justifies Buy Rating and $34 Price Target
- RegenXBio’s Strategic Manufacturing Edge and Market Position Justify Buy Rating
- RegenXBio Inc. Earnings Call: Positive Progress Amid Challenges
- Regenxbio price target raised to $25 from $24 at Morgan Stanley
- REGENXBIO Reports Q3 2025 Financial and Operational Progress